Astragaloside IV: a potential nemesis for gastric cancer
Frontiers in Pharmacology · 18.07.2025 · 16
DOI: 10.3389/fphar.2025.1636341 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.07.2025. Verfasst von Chao Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, Loujiang New City Hospital of Taicang (Taicang Branch of Ruijin Hospital Affiliated with Shanghai Jiao To…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer (GC), a life-threatening malignancy with profound global health impacts, remains a cardinal focus of biomedical research. Recently, astragaloside IV (AS-IV), a bioactive triterpenoid saponin derived from Astragalus mongholicus Bunge , has garnered substantial attention for its multifaceted anticancer properties in preclinical investigations. This review systematically synthesizes current evidence on the molecular mechanisms underlying AS-IV’s inhibitory effects against GC, encompassing programmed cell death pathways (apoptosis, autophagy, pyroptosis, ferroptosis), tumor angiogenesis, tumor microenvironment modulation, Helicobacter pylori and inflammatory signaling networks. Many studies demonstrate that AS-IV can inhibit the development of GC through multi-target and multi-pathway mechanisms, making it a well-deserved nemesis of GC. Notably, although AS-IV has emerged as a potential candidate for GC therapy, it suffers from problems such as single research model, unclear toxic and side effects, and poor bioavailability. These seriously hinder the efficiency of AS-IV in the treatment of GC. In the future, we can design and implement a series of in vivo and in vitro experiments to further explore and clarify the mechanism of action of AS-IV in the treatment of GC. It is encouraged to carry out a number of high-quality clinical controlled studies to further prove the effectiveness and safety of AS-IV. In addition, we can also use emerging technologies (such as nanotechnology) to improve the bioavailability of AS-IV, bringing more hope to GC patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, Loujiang New City Hospital of Taicang (Taicang Branch of Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine), Suzhou, China.
- Department of Hepatology, Yueyang Hospital of Integrated Traditional Chinese and Westen Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Gastroenterology, Loujiang New City Hospital of Taicang (Taicang Branch of Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine), Suzhou, China.
- Department of Public Health, Loujiang New City Hospital of Taicang (Taicang Branch of Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine), Suzhou, China.
- Department of Traditional Chinese Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Hu, C., Li, Q., Gong, S. N., Zou, X. J., Xu, J. Y., Ying, H. F., & Zheng, L. (2025). Astragaloside IV: a potential nemesis for gastric cancer. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1636341
Vancouver
Hu C, Li Q, Gong SN, Zou XJ, Xu JY, Ying HF, et al. Astragaloside IV: a potential nemesis for gastric cancer. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1636341
BibTeX
@article{Hu2025,
author = {Hu, Chao and Li, Qiong and Gong, Song-Nan and Zou, Xiao-Jie and Xu, Jia-Yue and Ying, Hai-Feng and Zheng, Lan},
title = {Astragaloside IV: a potential nemesis for gastric cancer},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1636341}
}
EUVIMED